Quantum Genomics Overview
- Founded
-
2006
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
ALQGC
- Investments
-
1
- Share Price
-
$0.18
- (As of Wednesday Closing)
Quantum Genomics General Information
Description
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PAR
Primary Office
- 33 rue Marbeuf
- 75008 Paris
- France
+33 01 00 00 00 00
Quantum Genomics Timeline
Quantum Genomics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.18 | $0.18 | $0.12 - $4.70 | $6.13M | 34.5M | 514K | -$0.92 |
Quantum Genomics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 43,085 | 106,208 | 148,559 | 51,698 |
| Revenue | 1,010 | 137 | 1,372 | 0 |
| EBITDA | (27,350) | (22,359) | (15,795) | (12,032) |
| Net Income | (24,775) | (19,574) | (13,151) | (10,163) |
| Total Assets | 28,265 | 25,572 | 42,990 | 16,922 |
| Total Debt | 3,546 | 3,400 | 2 | 2 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Quantum Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Quantum Genomics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardi
Biotechnology
Paris, France
9
As of 2022
00000
000000000
00000
000000
olore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000000000000
Burlington, MA
00
As of 0000
00000
0000000000 0
00000
000000
rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000 000000000
Prague, Czech Republic
0000
As of 0000
00.000
000000000
00.000
Add Comparison
Quantum Genomics Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cardurion Pharma | Venture Capital-Backed | Burlington, MA | 00 | 00000 | 0000000000 0 | 00000 |
| 0000000 | Private Equity-Backed | Prague, Czech Republic | 0000 | 00.000 | 000000000 | 00.000 |
Quantum Genomics Patents
Quantum Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013336738-A1 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | Active | 22-Oct-2012 | 0000000000 | |
| AU-2013336738-B2 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | Active | 22-Oct-2012 | 0000000000 | |
| CA-2884914-A1 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | Active | 22-Oct-2012 | 0000000000 | |
| EP-2722327-A1 | Crystalline phase of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with l-lysine | Inactive | 22-Oct-2012 | 0000000000 | |
| EP-2909169-B1 | Crystalline phase of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) with l-lysine | Active | 22-Oct-2012 | C07C319/28 |
Quantum Genomics Executive Team (8)
Quantum Genomics Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000000000 | Quantum Genomics | Board Member | 000 0000 |
| 000000000 0é0000 | Self | Board Member | 000 0000 |
| 0000-00000000 0000 | Quantum Genomics | Chief Executive Officer & Board Member | 000 0000 |
| 0000000 000000 | Quantum Genomics | Board Member & Managing Director of International Multifinance | 000 0000 |
Quantum Genomics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Quantum Genomics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Quantum Genomics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 29-Oct-2007 | 0000000000 | Consulting Services (B2B) | 000000 0é |
Quantum Genomics ESG
Risk Overview
Risk Rating
Updated December, 21, 2022
28.14 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 465
Rank
00.00
Percentile
Quantum Genomics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000000 | 29-Oct-2007 | 000000000000000000 | Completed |
|